January 6, 2010 - The American College of Nuclear Medicine (ACNM) is holding its annual meeting Jan. 27-28, 2010, in Albuquerque, N.M., in conjunction with the Society of Nuclear Medicine's (SNM) Mid-Winter Meeting.
The meeting, which provides attendees with the opportunity to earn up to 25 continuing education credits, will highlight the latest advancements in molecular imaging and nuclear medicine. The educational sessions will conclude with special workshops on nanomedicine and clinical trials.
The ACNM meeting will offer presentations on PET/CT of the head and neck, including thyroid cancer, chest and abdomen. ACNM will also offer lectures on the use of molecular imaging for lung scans and brain imaging and the use of new PET radiopharmaceuticals for treating disease. For nuclear medicine and radiology residents, ACNM will offer abstract presentations and a session on how to find a job in nuclear medicine.
SNM will offer a two-day CT case review workshop that will provide 16 hours of continuing education credit for physicians. SNM will also offer workshops on the use of molecular imaging for the diagnosis of neurodegenerative disorders, and diagnosis and treatment of heart failure. Sessions will take place Jan. 29-31.
SNM's Technologist Section (SNMTS) will host "The Sharp Edges of Nuclear Medicine: See What's New," Jan. 30-31,2010, to introduce technologists to new techniques in fusion imaging, with a focus on patients with epilepsy. SNMTS will also host a joint session with the American Society of Radiologic Technologists, focusing on legislative and regulatory issues facing nuclear medicine today, including USP and the Medicare Improvement Providers and Patients Act of 2008 (MIPPA).
SNM's Molecular Imaging Center of Excellence will host its annual summit on Jan. 31 and Feb. 1. This year's summit will focus on nanomedicine and molecular imaging. More than 20 experts from a variety of fields will examine current and potential uses of nanomaterials for patient care through improved diagnosis and individualized treatment strategies.
The week will cap off with SNM's Clinical Trials Workshop (CTN), Feb. 1-2, 2010. The CTN Workshop will expand on last year's successful meeting through in-depth presentations and discussions about how to expedite drug discovery, gain approval for new biomarkers, and comply with regulatory requirements in the U.S. and abroad. Featured seminars will cover the need for standardization in imaging trials, clinical research operating procedures, quality assurance, phantom utilization and good manufacturing practices. The CTN will host a special roundtable on the evening of Feb. 1 for leadership and senior staff at clinical research organizations. The CTN will also host sessions especially for nuclear medicine technologists about professional development opportunities in clinical trials research.
For more information: www.snm.org
April 23, 2024 
![(A) PET images of [68Ga]Ga-DOTA-ZCAM241 uptake at baseline and 3, 7, and 12 days after injection as inflammatory arthritis developed in single representative individual mouse. Images are normalized to SUV of 0.5 for direct comparison between time points. (B) CD69 immunofluorescence Sytox (Thermo Fisher Scientific) staining of joints of representative animals during matching time points.](/sites/default/files/styles/feed_medium/public/PET%20Tracers.jpeg?itok=P5Di6MIe)
